Sphingomyelin containing preparation
CA 2707691 C · Owner: Center For Molecular Medicine And Immunology · Inventors: Modrak, David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 24, 2000 and granted September 3, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 24, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 24, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.